Gnosis by Lesaffre launches private label, ready-to-market immune health product, MenaQ7 Protect


The ready-to-market solution produced in collaboration with Probiotical is the company’s first entry into the private label sector.

Photo ©

Photo ©

Gnosis by Lesaffre is launching its new MenaQ7 Protect stick packs for daily and long-term immune support in collaboration with Probiotical. The ready-to-market solution is the company’s first entry into the private label sector.

Each stick pack contains 1 billion cells each of Bifidobacterium animalis subsp. lactis BS01 (LMG-P-21384), Lacticaseibacillus rhamnosus LR04 (DSM 16605), and Bifidobacterium bifidum BB10 (DSM 33678), 75 mcg of MenaQ7 Vitamin K2 as MK-7, and 80 mg vitamin C. MenaQ7 Protect comes in an orange flavor that can be ingested directly or mixed into a beverage.

“Probiotics function in harmony with our immune system, effectively distinguishing allies from adversaries, and play a pivotal role in shielding us against harmful pathogens,” explains Vera Mogna, CEO of Probiotical, in a press release. “The probiotic strains selected for MenaQ7 Protect naturally occur in the human body and work in concert with the immune system to fortify the body’s defenses. Through meticulous research, we have selected strains that are able to uniquely interact with the immune system, creating a targeted approach to stimulate and fortify our natural defenses. This pioneering collaboration aims to harness the synergistic potential of our premium probiotic strains and MenaQ7, offering a promising new avenue to support and bolster immune health.”

This product also marks MenaQ7’s debut as an immunomodulator. Prior to this, the ingredient has been known for bone and cardiovascular support, however Gnosis cites in vitro research that found MenaQ7 delivers anti-inflammatory benefits1, reduces oxidative stress in muscle cells2, and early evidence that suggests vitamin K2 may even suppress T-cell activation and proliferation. The ingredient has also been shown to support lung health3 and reduce the risk of gut dysbiosis.4

“We are particularly excited about MenaQ7 Protect as it represents a foray into new areas for Gnosis, both in producing a finished product, but also shifting MenaQ7 into a new condition-specific arena,” said Philippe Caillat, global marketing director with Gnosis by Lesaffre, in a press release. “Immune health remains a shared common concern all year long and consumers consistently seek products that can optimize immune function continuously, while fitting into their lifestyles. MenaQ7 Protect perfectly fits this need while offering our customers a ready-to-market solution featuring our clinically proven MenaQ7 K2.”


  1. Pan, MH.; Maresz, K.; Lee, P.S.; Wu, J.C.; Ho, C.T.; Popko, J.; Mehta, D.S.; Stohs, S.J.; Badmaev, V. Inhibition of TNF-α, IL-1α, and IL-1β by Pretreatment of Human Monocyte-Derived Macrophages with Menaquinone-7 and Cell Activation with TLR Agonists In Vitro. J Med Food, 2016, 19(7): 663-9. DOI: 10.1089/jmf.2016.0030
  2. Akbulut, A.C.; Schurgers, L.J. Non-Canonical Role of MK-7 in Vascular Smooth Muscle Cells—Promoting Energy and Inhibiting of Oxidative Stress. Bio Life Sci Forum. 2022, 12(1): 3. DOI: 10.3390/IECN2022-12401
  3. Jespersen, T.; Kampmann, F.B.; Dantoff, T.M.; Jorgensen, N.R.; Kårhus, L.L.; Madsen, F.; Linneberg, A.; Thysen, S.M. The association of vitamin K status with lung function and disease in a general population. ERJ Open Research, 2023, 9: 00208-2023. DOI: 10.1183/23120541.00208-2023
  4. Lai, Y.; Masatoshi, H.; Ma, Y.; Guo, Y.; Zhang, B. Role of Vitamin K in Intestinal Health. Front Immunol. 2022, 12: 791565. DOI: 10.3389/fimmu.2021.791565
Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.